Long-term endoscopic surveillance for Barrett's esophagus in Japan: Multicenter prospective cohort study.
Barrett's esophagus
endoscopic surveillance
esophageal adenocarcinoma
incidence of cancer
Journal
Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
ISSN: 1443-1661
Titre abrégé: Dig Endosc
Pays: Australia
ID NLM: 9101419
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
revised:
01
12
2020
received:
23
09
2020
accepted:
01
12
2020
pubmed:
6
12
2020
medline:
9
11
2021
entrez:
5
12
2020
Statut:
ppublish
Résumé
Although a recent study showed the cancer incidence of Barrett's esophagus (BE) to be 1.2%/year in 251 patient-years in Japan, the long-term outcomes remain unclear. The present study estimated the cancer risk of BE in Japan using our original prospective multicenter cohort. A total of 98 patients with BE of maximum length of ≥2 cm were enrolled during the period of 2010-2012 and received at least one follow-up endoscopy over 5 years thereafter. Cancer incidence rates with 95% confidence interval for occurrence of esophageal adenocarcinoma (EAC) were calculated as the number of events divided by patient-years of follow-up and were expressed as %/year. Overall, the median endoscopic follow-up period was 59.9 (first and third quartiles, 48.5-60.8) months, constituting a total of 427 patient-years of observation. Since two EAC cases developed, the cancer incidence was 0.47% (0.01%-1.81%)/year. The cancer incidence was 0.39% (-0.16% to 2.44%) in 232 patient-years and 0.31% (-0.13% to 1.95%)/year in 318 patient-years for 55 cases with specialized intestinal metaplasia and 70 with BE ≥3 cm (maximum), respectively. At the end of follow-up, 12 of 92 patients (13.0%) died, but none died from EAC. This is the largest prospective follow-up study with endoscopy to investigate the incidence of EAC in unequivocal BE with the maximum length of ≥2 cm in Japan. Although a further large-scale study will be required to validate our results, the cancer risk of BE in Japan would be lower than previously reported (0.47% vs 1.2%/year).
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1085-1092Informations de copyright
© 2020 Japan Gastroenterological Endoscopy Society.
Références
Colquhoun A, Arnold M, Ferlay J, Goodman KJ, Forman D, Soerjomataram I. Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut 2015; 64: 1881-8.
McColl KEL. What is causing the rising incidence of esophageal adenocarcinoma in the West and will it also happen in the East? J Gastroenterol 2019; 54: 669-73.
de Jonge PJ, van Blankenstein M, Grady WM, Kuipers EJ. Barrett's oesophagus: Epidemiology, cancer risk and implications for management. Gut 2014; 63: 191-202.
Clermont M, Falk GW. Clinical guidelines update on the diagnosis and management of Barrett's esophagus. Dig Dis Sci 2018; 63: 2122-8.
Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: A new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94: 2043-53.
Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: A systematic review and meta-analysis. Am J Epidemiol 2008; 168: 237-49.
Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010; 8: 235-44.
Desai TK, Krishnan K, Samala N et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: A meta-analysis. Gut 2012; 61: 970-6.
Conio M, Blanchi S, Lapertosa G et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: A prospective study. Am J Gastroenterol 2003; 98: 1931-9.
Wani S, Falk G, Hall M et al. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011; 9: 220-7.
Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of Adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 2011; 365: 1375-83.
Bhat S, Coleman HG, Yousef F et al. Risk of malignant progression in Barrett’s esophagus patients: Results from a large population-based study. J Natl Cancer Inst 2011; 103: 1049-57.
de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett's oesophagus: A Dutch nationwide cohort study. Gut 2010; 59: 1030-6.
Koizumi S, Motoyama S, Iijima K. Is the incidence of esophageal adenocarcinoma increasing in Japan? Trends from the data of a hospital-based registration system in Akita Prefecture. Japan J Gastroenterol 2018; 5: 827-33.
Matsuno K, Ishihara R, Ohmori M et al. Time trends in the incidence of esophageal adenocarcinoma, gastric adenocarcinoma, and superficial esophagogastric junction adenocarcinoma. J Gastroenterol 2019; 54: 784-91.
Nishi T, Makuuchi H, Ozawa S, Shimada H, Chino O. The present status and future of Barrett's esophageal adenocarcinoma in Japan. Digestion 2019; 99: 185-90.
Fock KM, Talley N, Goh KL et al. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: An update focusing on refractory reflux disease and Barrett's oesophagus. Gut 2016; 65: 1402-15.
Shinkai H, Iijima K, Koike T et al. Association between the body mass index and the risk of Barrett's esophagus in Japan. Digestion 2014; 90: 1-9.
Sharma P, Dent J, Armstrong D et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: The Prague C & M criteria. Gastroenterology 2006; 131: 1392-9.
The Japan esophageal society. Japanese classification of esophageal cancer, tenth edition: part I. Esophagus 2009; 6: 1-25.
Matsuhashi N, Sakai E, Ohata K et al. Surveillance of patients with long-segment Barrett's esophagus: A multicenter prospective cohort study in Japan. J Gastroenterol Hepatol 2017; 32: 409-14.
Anaparthy R, Gaddam S, Kanakadandi V et al. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia. Clin Gastroenterol Hepatol 2013; 11: 1430-6.
Hamade N, Vennelaganti S, Parasa S et al. Lower annual rate of progression of short-segment vs long-segment Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2019; 17: 864-8.
Pohl H, Pech O, Arash H et al. Length of Barrett's oesophagus and cancer risk: Implications from a large sample of patients with early oesophageal adenocarcinoma. Gut 2016; 65: 196-201.
Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119: 333-8.
Kroep S, Lansdorp-Vogelaar I, Rubenstein JH et al. An accurate cancer incidence in Barrett's esophagus: A best estimate using published data and modeling. Gastroenterology 2015; 149: 577-85.
Martinez P, Timmer MR, Lau CT et al. Dynamic clonal equilibrium and predetermined cancer risk in Barrett's oesophagus. Nat Commun 2016; 7: 12158.
Peters Y, Honing J, Kievit W et al. Incidence of progression of persistent nondysplastic Barrett's esophagus to malignancy. Clin Gastroenterol Hepatol 2019; 17: 869-77.
Gaddam S, Singh M, Balasubramanian G et al. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: Results from a large multicenter cohort. Gastroenterology 2013; 145: 548-53.
Nguyen T, Thrift AP, Yu X, Duan Z, El-Serag HB. The annual risk of esophageal adenocarcinoma does not decrease over time in patients with Barrett's esophagus. Am J Gastroenterol 2017; 112: 1049-55.
Krishnamoorthi R, Ramos GP, Crews N et al. Persistence of nondysplastic Barrett's esophagus is not protective against progression to adenocarcinoma. Clin Gastroenterol Hepatol 2017; 15: 950-2.
Ishihara R, Goda K, Oyama T. Endoscopic diagnosis and treatment of esophageal adenocarcinoma: Introduction of Japan Esophageal Society classification of Barrett's esophagus. J Gastroenterol 2019; 54: 1-9.
Ishihara R, Arima M, Iizuka T et al. Japan Gastroenterological Endoscopy Society Guidelines Committee of ESD/EMR for Esophageal Cancer. Endoscopic submucosal dissection/endoscopic mucosal resection guidelines for esophageal cancer. Dig Endosc 2020; 32: 452-93.
Nakama H, Zhang B, Zhang X, Fukazawa K. Age-related cancer detection rate and costs for one cancer detected in one screening by immunochemical fecal occult blood test. Dis Colon Rectum 2001; 44: 1696-9.
Ross WA. Colorectal cancer screening in evolution: Japan and the USA. J Gastroenterol Hepatol 2010; 25(Suppl 1): S49-56.
Fitzgerald RC, di Pietro M, Ragunath K et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014; 63: 7-42.
Cook MB, Coburn SB, Lam JR, Taylor PR, Schneider JL, Corley DA. Cancer incidence and mortality risks in a large US Barrett's oesophagus cohort. Gut 2018; 67: 418-529.